Cite
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
MLA
Lam, Phillip H., et al. “Similar Clinical Benefits from Below-Target and Target Dose Enalapril in Patients with Heart Failure in the SOLVD Treatment Trial.” European Journal of Heart Failure, vol. 20, no. 2, Feb. 2018, pp. 359–69. EBSCOhost, https://doi.org/10.1002/ejhf.937.
APA
Lam, P. H., Dooley, D. J., Fonarow, G. C., Butler, J., Bhatt, D. L., Filippatos, G. S., Deedwania, P., Forman, D. E., White, M., Fletcher, R. D., Arundel, C., Blackman, M. R., Adamopoulos, C., Kanonidis, I. E., Aban, I. B., Patel, K., Aronow, W. S., Allman, R. M., Anker, S. D., & Pitt, B. (2018). Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. European Journal of Heart Failure, 20(2), 359–369. https://doi.org/10.1002/ejhf.937
Chicago
Lam, Phillip H., Daniel J. Dooley, Gregg C. Fonarow, Javed Butler, Deepak L. Bhatt, Gerasimos S. Filippatos, Prakash Deedwania, et al. 2018. “Similar Clinical Benefits from Below-Target and Target Dose Enalapril in Patients with Heart Failure in the SOLVD Treatment Trial.” European Journal of Heart Failure 20 (2): 359–69. doi:10.1002/ejhf.937.